Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: a case report

INTRODUCTION: Tyrosine kinase inhibitors are widely prescribed in thoracic oncology and have excellent responses as a first-line treatment for locally advanced or metastatic lung cancer with epidermal growth factor receptor mutations. The side effects of tyrosine kinase inhibitors are mostly gastroi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakhri, Linda, Meynet, Elodie, Ferrer, Léonie, Pirvu, Augustin, Ferretti, Gilbert, Moro-Sibilot, Denis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202250/
https://www.ncbi.nlm.nih.gov/pubmed/25301323
http://dx.doi.org/10.1186/1752-1947-8-335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202250/
https://www.ncbi.nlm.nih.gov/pubmed/25301323
http://dx.doi.org/10.1186/1752-1947-8-335

Ejemplares similares